GlassScriptPhysician profile
Mohammad A Khan
NPI 1639113285
$585.71
in general payments reported to CMS, 2019-2025
12 companies · $104 in 2025
The $104 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.92 · 2020: $34.70 · 2021: $86.77 · 2022: $80.21 · 2023: $80.00 · 2024: $125 · 2025: $104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $163.08 | 2019-2025 | |
| Corium, LLC | $101.01 | 2022-2023 | Azstarys |
| Sanofi-Aventis U.S. LLC | $81.76 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $80.01 | 2021-2025 | Vaxneuvance, Rotateq, Vaxelis |
| Ucb, INC. | $27.88 | 2022 | |
| Glaxosmithkline, LLC. | $26.82 | 2019-2025 | Pediarix, Bexsero |
| Incyte Corporation | $24.96 | 2019 | |
| Seqirus USA INC | $24.37 | 2024 | Flucelvax |
| Genentech USA, INC. | $17.24 | 2020 | |
| Shire North American Group INC | $13.03 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.01 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.